Skip to main content
Top
Published in: Clinical and Experimental Nephrology 5/2012

01-10-2012 | Images in Nephrology

Image of Erdheim–Chester disease requiring hemodialysis

Authors: Maki Tsukamoto, Masaaki Akahane, Masaomi Nangaku

Published in: Clinical and Experimental Nephrology | Issue 5/2012

Login to get access

Excerpt

Erdheim–Chester disease (ECD) is a rare, non-Langerhans form of histiocytosis, first described in 1930, with a wide range of manifestations through the xanthomatous infiltration of tissues [1]. A 52-year-old Japanese male who was diagnosed as ECD 6 years ago has been treated with IFN-α for preventing progression of cardiovascular and renal involvements. Computed tomography (CT) showed soft-tissue attenuation along the wall of the bilateral renal pelvis and ureter, enlarged right kidney, and thinned left renal parenchyma associated with hydronephrosis (Fig. 1). T2-weighted magnetic resonance imaging (MRI) showed low intensity along the wall of the bilateral renal pelvis and ureter, which suggested chronic inflammation or fibrosis rather than tumor or lymphoma (Fig. 2). Potential causes of renal dysfunction included chronic ureteral obstruction and xanthomatous invasion. As in this case, end stage renal disease requiring hemodialysis due to ECD is very rare, to our knowledge, but interferon-α treatment dramatically decreased mortality [2]. Follow-up of this case would be beneficial for management of hemodialysis in such patients.
Literature
1.
go back to reference Veyssier-Belot C, Cacoub P, Caparros-Lefebvre D, Wechsler J, Brun B, Remy M, et al. Erdheim–Chester disease. Clinical and radiologic characteristics of 59 cases. Medicine (Baltimore). 1996;75(3):157–69.CrossRef Veyssier-Belot C, Cacoub P, Caparros-Lefebvre D, Wechsler J, Brun B, Remy M, et al. Erdheim–Chester disease. Clinical and radiologic characteristics of 59 cases. Medicine (Baltimore). 1996;75(3):157–69.CrossRef
2.
Metadata
Title
Image of Erdheim–Chester disease requiring hemodialysis
Authors
Maki Tsukamoto
Masaaki Akahane
Masaomi Nangaku
Publication date
01-10-2012
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 5/2012
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-012-0675-6

Other articles of this Issue 5/2012

Clinical and Experimental Nephrology 5/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine